Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00365365 · ClinicalTrials.gov registry record · Phase 2
Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 214
- Enrollment target
NCT00365365 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 214 participants.
The verdict
NCT00365365, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 214 participants
- Enrollment target
Study Summary
This is a phase IIb, randomized, parallel-group, noncomparative, multicenter, pilot study designed to evaluate the safety and efficacy of bevacizumab with or without (+/-) trastuzumab administered with three different docetaxel-based combination regimens for the adjuvant treatment of participants with node positive or high-risk node negative breast cancer.
Interventions
- DRUG Doxorubicin and cyclophosphamide (AC) + bevacizumab
- DRUG Docetaxel (T) + bevacizumab
- DRUG Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab
- DRUG Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab
- DRUG Bevacizumab and trastuzumab maintenance therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 214 participants |
| Start Date | 2006-08 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00365365
The ClinicalTrials.gov registry entry for NCT00365365 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 214 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Doxorubicin and cyclophosphamide (AC) + bevacizumab is the first listed.
NCT00365365 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00365365 about?
NCT00365365 is a clinical study titled "Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer". This is a phase IIb, randomized, parallel-group, noncomparative, multicenter, pilot study designed to evaluate the safety and efficacy of bevacizumab with or without (+/-) trastuzumab administered with three different docetaxel-based combination regimens for the adjuvant treatment of participants wi...
What is the current status of trial NCT00365365?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 214 participants. The study started on 2006-08. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00365365?
The interventions under investigation include: Doxorubicin and cyclophosphamide (AC) + bevacizumab (DRUG), Docetaxel (T) + bevacizumab (DRUG), Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab (DRUG), Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab (DRUG), Bevacizumab and trastuzumab maintenance therapy (DRUG).
Who is sponsoring clinical trial NCT00365365?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.